Hymovis®, which was recently approved by the FDA in the U.S., is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties

PARSIPPANY, N.J., Nov. 2, 2015 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will present Hymovis® (high molecular weight viscoelastic hyaluronan) at the American…

Fidia Farmaceutici’s Italian excellence grows in the US market with its latest generation hyaluronic acid

The FDA’s Center for Devices and Radiological Health (CDRH) has approved the PMA (Pre Market Approval) application for Hymovis from Fidia Farmaceutici, indicated for the intra-articular therapy of osteoarthritis based on hyaluronic acid, designed to remain longer in the joint. This information comes…


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine